L Siangjong1,2, D H Goldman1, T Kriska1, K M Gauthier1, E M Smyth3, N Puli4, G Kumar4, J R Falck4, W B Campbell1. 1. Department of Pharmacology and Toxicology, Medical College of Wisconsin, Milwaukee, WI, USA. 2. Faculty of Pharmacy, Silpakorn University, Nakorn Pathom, Thailand. 3. Department of Pharmacology, University of Pennsylvania, Philadelphia, PA, USA. 4. Department of Biochemistry, University of Texas Southwestern Medical Center, Dallas, TX, USA.
Abstract
AIM: 12/15-lipoxygenase (12/15-LO) metabolizes arachidonic acid (AA) into several vasoactive eicosanoids. In mouse arteries, we previously characterized the enzyme's 15-LO metabolites 12(S)-hydroxyeicosatetraenoic acid (HETE), 15-HETE, hydroxyepoxyeicosatrienoic acids (HEETAs) and 11,12,15-trihydroxyeicosatrienoic acids (11,12,15-THETAs) as endothelium-derived relaxing factors. However, the observed 12-LO metabolites remained uncharacterized. The purpose of this study was to determine the structure and biological functions of eicosanoids generated by the enzyme's 12-LO activity. METHODS: Metabolites extracted from aortas of C57BL/6 male mice were separated using a series of reverse and normal phase chromatographic steps and identified as hepoxilin A3 , trioxilin A3 and trioxilin C3 by mass spectrometry. Activities of these natural compounds were tested on isometric tension and intracellular calcium release. The role of thromboxane (TP) receptor was determined in HEK293 cells overexpressing TPα receptor (TPα -HEK). RESULTS: All identified vascular 12-LO metabolites were biologically active. In mouse mesenteric arteries, trioxilin A3 , C3 and hepoxilin A3 (3 μm) relaxed arteries constricted with the thromboxane mimetic, U46619-constricted arteries (maximum relaxations of 78.9 ± 3.2, 29.7 ± 4.6, 82.2 ± 5.0 and 88.0 ± 2.4% respectively), but not phenylephrine-constricted arteries. In TPα-HEK cells, trioxilin A3 , C3 and hepoxilin A3 (10 μm) inhibited U46619 (10 nM)-induced increases in intracellular calcium by 53.0 ± 7.2%, 32.8 ± 5.0% and 37.9 ± 13.5% respectively. In contrast, trioxilin B3 and hepoxilin B3 were not synthesized in arteries and exhibited little biological activity. CONCLUSION: Trioxilin A3 and C3 and hepoxilin A3 are endogenous vascular relaxing factors. They are not endothelium-derived hyperpolarizing factors but mediate vascular relaxation by inhibiting TP agonist-induced increases in intracellular calcium. Thus, they regulate vascular homeostasis by acting as endogenous TP antagonists.
AIM: 12/15-lipoxygenase (12/15-LO) metabolizes arachidonic acid (AA) into several vasoactive eicosanoids. In mouse arteries, we previously characterized the enzyme's 15-LO metabolites 12(S)-hydroxyeicosatetraenoic acid (HETE), 15-HETE, hydroxyepoxyeicosatrienoic acids (HEETAs) and 11,12,15-trihydroxyeicosatrienoic acids (11,12,15-THETAs) as endothelium-derived relaxing factors. However, the observed 12-LO metabolites remained uncharacterized. The purpose of this study was to determine the structure and biological functions of eicosanoids generated by the enzyme's 12-LO activity. METHODS: Metabolites extracted from aortas of C57BL/6 male mice were separated using a series of reverse and normal phase chromatographic steps and identified as hepoxilin A3 , trioxilin A3 and trioxilin C3 by mass spectrometry. Activities of these natural compounds were tested on isometric tension and intracellular calcium release. The role of thromboxane (TP) receptor was determined in HEK293 cells overexpressing TPα receptor (TPα -HEK). RESULTS: All identified vascular 12-LO metabolites were biologically active. In mouse mesenteric arteries, trioxilin A3 , C3 and hepoxilin A3 (3 μm) relaxed arteries constricted with the thromboxane mimetic, U46619-constricted arteries (maximum relaxations of 78.9 ± 3.2, 29.7 ± 4.6, 82.2 ± 5.0 and 88.0 ± 2.4% respectively), but not phenylephrine-constricted arteries. In TPα-HEK cells, trioxilin A3 , C3 and hepoxilin A3 (10 μm) inhibited U46619 (10 nM)-induced increases in intracellular calcium by 53.0 ± 7.2%, 32.8 ± 5.0% and 37.9 ± 13.5% respectively. In contrast, trioxilin B3 and hepoxilin B3 were not synthesized in arteries and exhibited little biological activity. CONCLUSION:Trioxilin A3 and C3 and hepoxilin A3 are endogenous vascular relaxing factors. They are not endothelium-derived hyperpolarizing factors but mediate vascular relaxation by inhibiting TP agonist-induced increases in intracellular calcium. Thus, they regulate vascular homeostasis by acting as endogenous TP antagonists.
Authors: Kathryn M Gauthier; Yuttana Chawengsub; Daniel H Goldman; Raymond E Conrow; Siddam Anjaiah; J R Falck; William B Campbell Journal: Am J Physiol Heart Circ Physiol Date: 2008-01-18 Impact factor: 4.733
Authors: Lijie Cui; Marilyn A Isbell; Yuttana Chawengsub; John R Falck; William B Campbell; Kasem Nithipatikom Journal: J Am Soc Mass Spectrom Date: 2008-01-31 Impact factor: 3.109
Authors: Yuttana Chawengsub; Nitin T Aggarwal; Kasem Nithipatikom; Kathryn M Gauthier; Siddam Anjaiah; Bruce D Hammock; John R Falck; William B Campbell Journal: Am J Physiol Heart Circ Physiol Date: 2008-01-11 Impact factor: 4.733
Authors: Tamas Kriska; Anja Herrnreiter; Sandra L Pfister; Adeniyi Adebesin; John R Falck; William B Campbell Journal: Hypertension Date: 2021-11-17 Impact factor: 10.190
Authors: Takahito Chiba; Christopher P Thomas; M Wade Calcutt; William E Boeglin; Valerie B O'Donnell; Alan R Brash Journal: J Biol Chem Date: 2016-05-05 Impact factor: 5.157
Authors: Teng Li; Yuanyuan Zhong; Tao Tang; Jiekun Luo; Hanjin Cui; Rong Fan; Yang Wang; Dongsheng Wang Journal: Drug Des Devel Ther Date: 2018-11-01 Impact factor: 4.162
Authors: Joseph C Mays; Michael C Kelly; Steven L Coon; Lynne Holtzclaw; Martin F Rath; Matthew W Kelley; David C Klein Journal: PLoS One Date: 2018-10-22 Impact factor: 3.240